ANYL 190 |
| Within the realm of preclinical pharmaceutical evaluation, we are at a point where we can ask if the early promise of metabonomics has been realized or not. While the hope for a rapid throughput safety screen has not disappeared, the complexity of basic biochemistry stymies simplicity. The benefits of understanding this complexity may allow us to understand what we have always attributed to inter-animal or inter-study variation. This in turn may allow us to run studies with fewer animals and explain the odd responder that frequently reduces apparent safety margins. Metabonomics enables early and rapid assessment of safety related issues at a depth of biochemical analysis that was previously impractical, with mechanisms and safety biomarkers a frequent byproduct. This presentation will elaborate on the applications of metabonomics in preclinical safety assessment, what has worked and what still needs to be worked out with regard to screening, biomarkers and mechanistic toxicology. |
|
Development and Applications of Metabonomic/Metabolomic Methods of Analysis
8:30 AM-11:35 AM, Monday, 11 September 2006 Moscone Center -- Room 124, Oral
Division of Analytical Chemistry |